Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

This study tests whether combining blinatumomab (a drug that helps the immune system attack leukemia cells) with reduced-dose chemotherapy is safe and effective for newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) that does not carry the Philadelphia chromosome mutation. **You may be eligible if...** - You are between 15 and 59 years old - You have newly diagnosed B-cell acute lymphoblastic leukemia (Philadelphia chromosome-negative) - You are in reasonably good physical condition (ECOG 0–2) - Your expected survival is at least 2 months - Your organ function is adequate **You may NOT be eligible if...** - The leukemia has spread to your brain or spinal fluid - You have severe heart, liver, kidney, or lung problems - Your heart pumping function (LVEF) is below 45% - You have had another cancer in the past 5 years - You have HIV Talk to your doctor to see if this trial is right for you.